Editorial: Coronavirus disease 2019 (COVID-19) – advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges

Niederman, Michael S.; Zumla, Alimuddin

doi:10.1097/mcp.0000000000000771

Cited by 4 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all countries affected by COVID-19 in early 2020, EDs and ICUs admitted mostly COVID-19 patients. There was a global increase in the reported infection rate and mortality [ 3 , 12 , 13 ]. However, literature reported many patients with COVID-19 presenting with silent hypoxia [ [14] , [15] , [16] ].…”

Section: Discussionmentioning

confidence: 99%

Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study

Alhusain¹,

Alromaih²,

Alhajress³

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

Background Patients with COVID-19 usually present with fever and respiratory symptoms such as cough, sputum production, and dyspnea. However, they may suffer from severe hypoxemia without a clinical correlation with the respiratory symptoms, also known as silent or apathetic hypoxia. The aim of the study was to assess the predictors and clinical outcomes of COVID-19 patients without dyspnea. Methods A single-center retrospective cohort study, based on data extracted from the electronic hospital information system, with COVID-19 patients over a 10-month period in Riyadh, Saudi Arabia. Results Of the COVID-19 patients presenting at the Emergency Department with a SpO2 < 90%, 13% had silent hypoxia. The majority of the patients required BiPAP, 34% were intubated and 60% were admitted to an intensive care unit. There was no association between dyspnea and gender, age group, body mass index, or comorbidity. Cough, fever, and chronic cardiac diseases were predictive for dyspnea in a regression analysis. There was no difference in the clinical outcome between patients with silent dyspnea or dyspnea. Age and obesity were significantly associated with a decrease in survival, and an increase in the initial SpO2 increased survival. Conclusion Patients with cardiac disease are more likely to present with silent hypoxia. The SpO2 saturation in COVID-19 may be an independent predictor of survival. Silent hypoxia in COVID-19 patients does not appear to have an association with increase in mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study

Alhusain¹,

Alromaih²,

Alhajress³

et al. 2021

Journal of Infection and Public Health

View full text Add to dashboard Cite

show abstract

In silico evaluation of the inhibitory potential of nucleocapsid inhibitors of SARS-CoV-2: a binding and energetic perspective

Haque

Kumar

Mathkor

et al. 2022

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

Characterization of QuantiFERON Severe Acute Respiratory Syndrome Coronavirus 2 and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid and S1 Spike Protein Antibodies in Vaccinated and Unvaccinated Coronavirus Disease 2019 Patients

Mortaz,

Roofchayee,

Jamaati

et al. 2024

Biomedical and Biotechnology Research Journal

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) vaccination has been shown to elicit both humoral (antibody) and cell-mediated (T-cell) immune responses. This study aimed to characterize and compare the QuantiFERON severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and anti-SARS-CoV-2 antibody responses in vaccinated and unvaccinated COVID-19 patients, as well as vaccinated healthy controls (HCs). Methods: A total of 96 COVID-19 patients (68 vaccinated with Sinopharm and 15 with AstraZeneca), 13 unvaccinated COVID-19 patients, and 16 vaccinated HCs (8 Sinopharm and 8 AstraZeneca) were included. Serum antibodies against the SARS-CoV-2 spike (S1) protein and nucleocapsid (N) protein were measured by enzyme-linked immunosorbent assay. T-cell responses were evaluated using the QuantiFERON assay against three SARS-CoV-2 viral antigens (Ag1, Ag2, and Ag3). Results: There were no significant differences in S1 antibody levels between COVID-19 patients (vaccinated or unvaccinated) and HCs. However, 100% of unvaccinated COVID-19 patients had anti-N antibodies, which was significantly higher than the AstraZeneca-vaccinated group. T-cell responses did not differ significantly between vaccinated and unvaccinated patients or between vaccinated patients and HCs. Vaccination with Sinopharm induced higher levels of total N antibodies and greater interferon-gamma release against the viral antigens compared to the other groups. Conclusions: Vaccination, especially with Sinopharm, induced robust humoral (N antibodies) and cellular (T-cell) immune responses in COVID-19 patients. The findings highlight the importance of vaccination in eliciting a comprehensive immune response against SARS-CoV-2, even in the context of prior infection.

show abstract

Editorial: Coronavirus disease 2019 (COVID-19) – advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges

Cited by 4 publications

References 22 publications

Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study

Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study

In silico evaluation of the inhibitory potential of nucleocapsid inhibitors of SARS-CoV-2: a binding and energetic perspective

Characterization of QuantiFERON Severe Acute Respiratory Syndrome Coronavirus 2 and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid and S1 Spike Protein Antibodies in Vaccinated and Unvaccinated Coronavirus Disease 2019 Patients

Contact Info

Product

Resources

About